INSIGHTS ON DRUG DEVELOPMENT

DRUG DEVELOPMENT SOLUTIONS

  • Are you using obsolete or aging instruments simply because they continue to work? Running your laboratory with outdated technology brings about challenges beyond just headaches. Older technology may limit your performance, increase your costs, and open your lab up to risk. It may be time to investigate the real cost of using obsolete technology.

    With the Waters FlexUP Technology Renewal Program, always work with the latest technology for optimum productivity and security.

  • LMD 6 Laser Microdissection Microscope

    Dissection Perfection

    Laser Microdissection (LMD, also known as Laser Capture Microdissection or LCM) enables users to isolate specific single cells or entire areas of tissue. Powered by a unique laser design and dynamic software, Leica LMD systems allow users to easily isolate Regions of Interest (ROI) from entire areas of tissue down to single cells or even subcellular structures such as chromosomes.

    LMD is typically used in genomics (DNA), transcriptomics (mRNA, miRNA), proteomics, metabolomics, and even next generation sequencing (NGS). Researchers in neurology, cancer research, plant analysis, forensics or climate research rely on this method. Furthermore, LMD is a perfect tool for live cell culture (LCC), for cloning and re-cultivation, manipulation or downstream analysis.

    We move the laser, not the sample. And we use gravity for collection. That is why our LMD systems provide you with perfectly cut, contamination-free, analysis-ready dissectates.

  • In the pharmaceutical industry, every capsule and tablet begins with a concept. Transforming that idea into a tangible product requires an expert manufacturing partner. Natoli stands out as a leader in pharmaceutical equipment and services, providing a comprehensive journey from formulation to full-scale production.

  • We deliver custom assay development, screening, potency, and selectivity testing services for the pharmaceutical, biopharmaceutical, and agrochemical industries.

  • This pipeline outlines a sequence of late‑stage and emerging therapeutics projected to launch between 2024 and 2031, spanning immunology, neurology, psychiatry, rare disease, oncology, and inflammatory disorders.